The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 16, 2015

Filed:

Jun. 19, 2014
Applicant:

Vision Global Holdings Ltd., Hong Kong, HK;

Inventors:

Bing Lou Wong, Irvine, CA (US);

Norman Fung Man Wai, Vancouver, CA;

Sui Yi Kwok, Hong Kong, HK;

Sze Hang Lau, Hong Kong, HK;

Assignee:

VISION GLOBAL HOLDINGS LTD., Sheung Wan, HK;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61K 38/42 (2006.01); A61K 45/06 (2006.01); A61K 33/38 (2006.01); A61K 31/513 (2006.01); A61K 38/05 (2006.01); A61N 5/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/42 (2013.01); A61K 45/06 (2013.01); A61K 33/38 (2013.01); A61K 31/513 (2013.01); A61K 38/05 (2013.01); A61N 5/00 (2013.01);
Abstract

The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, Bortezomib, doxorubicin, cisplatin, or any combination thereof. The hemoglobin-based oxygen carrier in the composition is capable of targeting a surface receptor expressed on cancerous cells and facilitating the uptake of both hemoglobin-based oxygen carrier and the chemotherapeutic agent by the cancerous cells via a receptor-mediated mechanism. The hemoglobin-based oxygen carrier inhibits the expression of hypoxic response elements such as HIF1 α, VEGF, ET1, VHL, etc. The pharmaceutical composition of the present invention is also useful for inducing the apoptosis or cell death of a type of self-renewing and tumor-initiating cells called cancer stem cells which are located in the hypoxic niche of a cancerous tumor.


Find Patent Forward Citations

Loading…